脑小血管病脑白质高信号与认知障碍的关系研究进展

doi:10.3969/j.issn.1673-5765.2019.11.013

摘要/Abstract

摘要：

脑小血管病（cerebral small vessel disease，CSVD）是临床上常见的一类与年龄相关的脑血管疾病。脑白质高信号（white matter hypertensities，WMH）是CSVD的影像标志物之一。WMH患病率极高，与认知障碍的发生发展密切相关，但其影像表现及临床症状的异质性为早期发现、早期诊断带来了困难。本文从病理学、影像学及生物学3方面对WMH发生发展及其导致认知障碍的机制研究现况进行综述，同时总结目前的治疗策略，提出了接下来的研究目标及方向：能够反映预后的标志物及预测模型的研究，WMH发生发展的病理生理学机制研究，针对早期干预、药物开发的潜在靶点的研究等。

文章导读： 本文回顾了脑小血管病所致脑白质高信号及其与认知障碍相关领域的研究现状，介绍了研究进展和进一步的研究方向。

关键词: 脑小血管病; 脑白质高信号; 认知障碍

Abstract:

Cerebral small vascular disease (CSVD) is one of the most common age-related cerebrovascular diseases. White matter hyperintensity (WMH) of presumed vascular origin is one of the imaging markers of CSVD. The prevalence of WMH is extremely high, and which is closely related to the occurrence and development of cognitive impairment. However, the heterogeneity of imaging manifestations and clinical symptoms of WMH brings some difficulties to early detection and diagnosis. What’s more, the potential mechanism for disease development is not clear, so it leads to a relative lag in prevention and treatment of these diseases. This paper reviewed the current state of research on the mechanisms of cognitive impairment in the development of WMH from pathology, imaging and biology, and summarized the current treatment strategies, and raised some research objectives and directions in the next, for example, to establish the biomarkers and prediction model for assessing prognosis, to explore pathophysiological mechanism of WMH development, and find new potential targets for early intervention.

Key words: Cerebral small vascular disease; White matter hyperintensity; Cognitive impairment

王兴, 施余露, 陈奕奕, 王伊龙. 脑小血管病脑白质高信号与认知障碍的关系研究进展[J]. 中国卒中杂志, 2019, 14(11): 1146-1152.

WANG Xing, SHI Yu-Lu, CHEN Yi-Yi, WANG Yi-Long. Advances in the Relationship between White Matter Hyperintensity and Cognitive Impairment in Cerebral SmallVessel Disease[J]. Chinese Journal of Stroke, 2019, 14(11): 1146-1152.

参考文献

[1] PANTONI L. Cerebral small vessel disease：from

pathogenesis and clinical characteristics to

therapeutic challenges[J]. Lancet Neurol，2010，9

（7）：689-701.

[2] WARDLAW J M，SMITH E E，BIESSELS G J，et

al. Neuroimaging standards for research into small

vessel disease and its contribution to ageing and

neurodegeneration[J]. Lancet Neurol，2013，12（8）：

822-838.

[3] DE LEEUW F E，DE GROOT J C，OUDKERK M，

et al. Hypertension and cerebral white matter lesions

in a prospective cohort study[J]. Brain，2002，125

（Pt 4）：765-772.

[4] WOLTERS F J，ZONNEVELD H I，HOFMAN A，

et al. Cerebral perfusion and the risk of dementia：a

population-based study[J]. Circulation，2017，136

（8）：719-728.

[5] DEBETTE S，MARKUS H S. The clinical

importance of white matter hyperintensities on brain

magnetic resonance imaging：systematic review and

meta-analysis[J/OL]. BMJ，2010，341：c3666.

https：//doi.org/10.1136/bmj.c3666.

[6] SCHENK C，WUERZ T，LERNER A J. Small

vessel disease and memory loss：what the clinician

needs to know to preserve patients' brain health[J].

Curr Cardiol Rep，2013，15（12）：427.

[7] HABES M，ERUS G，TOLEDO J B，et al. White

matter hyperintensities and imaging patterns of brain

ageing in the general population[J]. Brain，2016，139

（Pt 4）：1164-1179.

[8] INZITARI D，PRACUCCI G，POGGESI A，et al.

Changes in white matter as determinant of global

functional decline in older independent outpatients：

three year follow-up of LADIS（leukoaraiosis and

disability）study cohort[J/OL]. BMJ，2009，339：

b2477. https：//doi.org/10.1136/bmj.b2477.

[9] PAVLOVIC A M，PEKMEZOVIC T，TOMIC

G，et al. Baseline predictors of cognitive decline

in patients with cerebral small vessel disease[J]. J

Alzheimers Dis，2014，42（Suppl 3）：S37-S43.

[10] BENEDICTUS M R，VAN HARTEN A C，

LEEUWIS A E，et al. White matter hyperintensities

relate to clinical progression in subjective cognitive

decline[J]. Stroke，2015，46（9）：2661-2664.

[11] JOKINEN H，KALSKA H，YLIKOSKI R，et

al. Longitudinal cognitive decline in subcortical

ischemic vascular disease--the LADIS study[J].

Cerebrovasc Dis，2009，27（4）：384-391.

[12] CHARIDIMOU A，FRIEDRICH J O，

GREENBERG S M，et al. Core cerebrospinal

fluid biomarker profile in cerebral amyloid

angiopathy：a meta-analysis[J/OL]. Neurology，

2018，90（9）：e754-e762. https：//doi.org/10.1212/

WNL.0000000000005030.

[13] PANTONI L，SIMONI M. Pathophysiology

of cerebral small vessels in vascular cognitive

impairment[J]. Int Psychogeriatr，2003，15（Suppl 1）：

59-65.

[14] DE GUIO F，VIGNAUD A，CHABRIAT H，et al.

Different types of white matter hyperintensities in

CADASIL：insights from 7-Tesla MRI[J]. J Cereb

Blood Flow Metab，2018，38（9）：1654-1663. [15] PRINS N D，SCHELTENS P. White matter

hyperintensities，cognitive impairment and dementia：

an update[J]. Nat Rev Neurol，2015，11（3）：157-165.

[16] Englund E. Neuropathology of white matter lesions

in vascular cognitive impairment[J]. Cerebrovasc

Dis，2002，13（Suppl 2）：11-15.

[17] DE GROOT M，VERHAAREN B F，DE BOER

R，et al. Changes in normal-appearing white matter

precede development of white matter lesions[J].

Stroke，2013，44（4）：1037-1042.

[18] KLOPPENBORG R P，NEDERKOORN P J，

GEERLINGS，M I，et al. Presence and progression

of white matter hyperintensities and cognition：a

meta-analysis[J]. Neurology，2014，82（23）：2127-

2138.

[19] SIVAKUMAR L，RIAZ1 P，KATE M，et al. White

matter hyperintensity volume predicts persistent

cognitive impairment in transient ischemic attack

and minor stroke[J]. Int J Stroke，2017，12（3）：264-

272.

[20] ALBER J，ALLADI S，BAE H J，et al. White

matter hyperintensities in vascular contributions

to cognitive impairment and dementia（VCID）：

knowledge gaps and opportunities[J/OL]. Alzheimers

Dement（N Y），2019，5：107-117. https：//doi.

org/10.1016/j.trci.2019.02.001.

[21] The LADIS Study Group. 2001–2011：a decade of

the LADIS（Leukoaraiosis And DISability）study：

what have we learned about white matter changes

and small-vessel disease?[J]. Cerebrovasc Dis，2011，

32（6）：577-588.

[22] SMITH E E，SALAT D H，JENG J，et al.

Correlations between MRI white matter lesion

location and executive function and episodic

memory[J]. Neurology，2011，76（17）：1492-1499.

[23] NEKOVAROVA T，FAJNEROVA I，HORACEK J，

et al. Bridging disparate symptoms of schizophrenia：

a triple network dysfunction theory[J/OL]. Front

Behav Neurosci，2014，8：171. https：//doi.

org/10.3389/fnbeh.2014.00171.

[24] DEY A K，STAMENOVA V，TURNER G，et al.

Pathoconnectomics of cognitive impairment in small

vessel disease：a systematic review[J]. Alzheimers

Dement，2016，12（7）：831-845.

[25] MASCALCHI M，GINESTRONI A，TOSCHI N，et

al. The burden of microstructural damage modulates

cortical activation in elderly subjects with MCI and

leuko-araiosis. A DTI and fMRI study[J]. Hum

Brain Mapp，2014，35（3）：819-830.

[26] DUERING M，FINSTERWALDER S，BAYKARA

E，et al. Free water determines diffusion alterations

and clinical status in cerebral small vessel disease[J].

Alzheimers Dement，2018，14（6）：764-774.

[27] TOMIMOTO H. White matter integrity and

cognitive dysfunction：radiological and

neuropsychological correlations[J]. Geriatr Gerontol

Int，2015，15（Suppl 1）：3-9.

[28] O'SULLIVAN M. Imaging small vessel disease

lesion topography，networks，and cognitive deficits

investigated with MRI[J]. Stroke，2010，41（10

Suppl）：154-158.

[29] KIUCHI K，MORIKAWA M，TAOKA T，et al.

White matter changes in dementia with Lewy bodies

and Alzheimer's disease：a tractography-based

study[J]. J Psychiatr Res，2011，45（8）：1095-1100.

[30] OTSUKA Y，YAMAUCHI H，SAWAMOTO N，et

al. Diffuse tract damage in the hemispheric deep

white matter may correlate with global cognitive

impairment and callosal atrophy in patients with

extensive leukoaraiosis[J]. AJNR Am J Neuroradiol，

2012，33（4）：726-732.

[31] LI Y，LI M，ZHANG X，et al. Higher blood-brain

barrier permeability is associated with higher white

matter hyperintensities burden[J]. J Neurol，2017，

264（7）：1474-1481.

[32] FARRALL A J，WARDLAW J M. Blood-brain

barrier：ageing and microvascular disease--

systematic review and meta-analysis[J]. Neurobiol

Aging，2009，30（3）：337-352.

[33] WARDLAW J M，SANDERCOCK P A，DENNIS

M S，et al. Is breakdown of the blood-brain barrier

responsible for lacunar stroke，leukoaraiosis，and

dementia?[J]. Stroke，2003，34（3）：806-812.

[34] ZHANG C E，WONG S M，VAN DE HAAR H J，et

al. Blood-brain barrier leakage is more widespread

in patients with cerebral small vessel disease[J].

Neurology，2017，88（5）：426-432.

[35] SWEENEY M D，ZHAO Z，MONTAGNE A，et al.

Blood-brain barrier：from physiology to disease and

back[J]. Physiol Rev，2019，99（1）：21-78.

[36] GASPAROVIC C，PRESTOPNIK J，THOMPSON

J，et al. 1H-MR spectroscopy metabolite levels

correlate with executive function in vascular

cognitive impairment[J]. J Neurol Neurosurg

Psychiatry，2013，84（7）：715-721.

[37] SCHUITEMAKER A，DIK M G，VEERHUIS R，et

al. Inflammatory markers in AD and MCI patients

with different biomarker profiles[J]. Neurobiol Aging，

2009，30（11）：1885-1889.

[38] OXENKRUG G F. Genetic and hormonal regulation

of tryptophan kynurenine metabolism：implications

for vascular cognitive impairment，major depressive disorder，and aging[J/OL]. Ann N Y Acad Sci，2007，

1122：35-49. https：//doi.org/10.1196/annals.1403.003.

[39] KALHEIM L F，BJØRNERUD A，FLADBY T，et

al. White matter hyperintensity microstructure in

amyloid dysmetabolism[J]. J Cereb Blood Flow

Metab，2017，37（1）：356-365.

[40] KIM H J，PARK S，CHO H，et al. Assessment

of extent and role of tau in subcortical vascular

cognitive impairment using 18F-AV1451 positron

emission tomography imaging[J]. JAMA Neurol，

2018，75（8）：999-1007.

[41] ROMÁN G C，KALARIA R N. Vascular

determinants of cholinergic deficits in Alzheimer

disease and vascular dementia[J]. Neurobiol Aging，

2006，27（12）：1769-1785.

[42] WANG M，NORMAN J E，SRINIVASAN V J，et

al. Metabolic，inflammatory，and microvascular

determinants of white matter disease and cognitive

decline[J]. Am J Neurodegener Dis，2016，5（5）：

171-177.

[43] NELSON A R，SWEENEY M D，SAGARE A P，et

al. Neurovascular dysfunction and neurodegeneration

in dementia and Alzheimer's disease[J]. Biochim

Biophys Acta，2016，1862（5）：887-900.

[44] KIMURA S，SAITO H，MINAMI M，et al.

Pathogenesis of vascular dementia in stroke-prone

spontaneously hypertensive rats[J]. Toxicology，

2000，153（1-3）：167-178.

[45] SACHDEV P S，VALENZUELA M J，BRODATY

H，et al. Homocysteine as a risk factor for cognitive

impairment in stroke patients[J]. Dement Geriatr

Cogn Disord，2003，15（3）：155-162.